Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes - Concepedia

Concepedia

Publication | Open Access

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

DOI Full Paper Access

1.8K

Citations

21

References

2019

Year

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen,

New England Journal of Medicine

Abstract

Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.

References

	Year	Citations
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes Bernard Zinman, Christoph Wanner, John M. Lachin, New England Journal of Medicine	2015	11.6K
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, New England Journal of Medicine	2017	7.5K
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen, New England Journal of Medicine	2016	7K
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, New England Journal of Medicine	2018	6K
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Melanie J. Davies, David A. D’Alessio, Judith Fradkin, Diabetes Care	2018	3.4K
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseHealth PolicyCardiovascular Outcomes	2019	2.8K
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome Marc A. Pfeffer, Brian Claggett, Rafael Díaz, New England Journal of Medicine	2015	2.3K
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz, New England Journal of Medicine	2017	2.1K
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Donna K. Arnett, Roger S. Blumenthal, Michelle A. Albert, Journal of the American College of Cardiology Preventive MedicineHealth PolicyCardiovascular DiseaseDisease PreventionHealth Promotion	2019	1.8K
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, The Lancet Diabetes ManagementCardiovascular DiseaseDiabetesClinical TrialsType 2	2018	1.7K

Page 1